Trehalose in Subjects With Neuronal Ceroid Lipofuscinoses — 3AL-CLN36

Neuronal Ceroid-Lipofuscinoses Clinical Trial

Official title:
A Study in Subjects With Neuronal Ceroid Lipofuscinoses Taking Trehalose

Status Completed

Clinical Trial Summary

Neuronal Ceroid Lipofuscinoses (NCL) or Batten's disease are the most common juvenile neurodegenerative disease, characterized by early blindness, movement disorders, cognitive and behavioral impairment, epilepsy, and retinopathy. This study aims to collect clinical and laboratory data of patients with NCL taking Trehalose.

Clinical Trial Description

This study aims to collect clinical and laboratory data of patients with NCL taking Trehalose. ;

Study Design

Related Conditions & MeSH terms

Neuronal Ceroid-Lipofuscinoses

Clinical Trial Details

NCT number	NCT04808297
Study type	Observational
Source	IRCCS Fondazione Stella Maris
Contact
Status	Completed
Phase
Start date	August 1, 2020
Completion date	October 1, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Active, not recruiting	`NCT04098211` - Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients
	Enrolling by invitation	`NCT03862274` - Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease